AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
Hormone Receptor-Positive Breast Cancer in 2026: Navigating a More Complex Treatment Landscape
By Christos Vaklavas, MD
The treatment algorithm for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer has grown substantially more complex over the past several years
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Refining the Approach to Advanced Ovarian Cancer: New Data From ASCO 2026
By Sindhu Priya Devarashetty, MD
Platinum-resistant ovarian cancer remains one of the more difficult clinical scenarios in gynecologic oncology, with a historical overall survival of roughly one year and limited options beyond weekly paclitaxel with or without bevacizumab.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Small Cell Lung Cancer in 2026: Tarlatamab Changes the Arc, and a New Wave of ADCs Is Coming
By Rafael Santana-Davila, MD
Tarlatamab has changed the arc of small cell lung cancer — the first treatment in years to improve survival in the second-line setting. Dr. Rafael Santana-Davila maps the 2026 landscape and the ADC wave that's coming.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Relapsed and Refractory DLBCL in 2026: More Options Than Ever, and Three Questions That Actually Matter
By Timothy Fenske, MD
Four of the five randomized R/R DLBCL trials showing overall survival benefit have come in the last four years. Dr. Timothy Fenske maps the 2026 options and the three questions that actually guide treatment selection.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Daraxonrasib and the RASolute 302 Trial: A Paradigm Shift in the RAS Targeting Era and Management of Pancreatic Cancer
By Meghana Singh, MD; Ibrahim Halil Sahin, MD
For the first time, a targeted therapy has doubled overall survival in second-line metastatic pancreatic cancer. Two oncologists break down the RASolute 302 trial and what daraxonrasib means for the field.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
Multiple Myeloma in 2026: Redefining the Possible — From Three-Year Median Survival to the Threshold of Cure
By Shaji K. Kumar, MD
Median survival in multiple myeloma has grown from three years to potentially fifteen. Dr. Shaji Kumar maps the 2026 treatment landscape — from quadruplet induction to immunotherapy in first relapse and the threshold of cure.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
ASCO 2026: Sima Ehsani Chimeh, MD, on the VIKTORIA-1 Trial in HR+/HER2-Negative Advanced Breast Cancer
By The Cancer News Team
VIKTORIA-1 data show gedatolisib roughly doubled PFS versus alpelisib in PIK3CA-mutant HR+/HER2-negative advanced breast cancer — with a more favorable tolerability profile. An expert breaks down the findings.
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).
CAR-T's Real Toxicity Is Delay
By Carolina Escobar, MD
CAR-T physician training centers on managing key toxicities: CRS (fever, hypotension, organ dysfunction) and ICANS (confusion, tremors, seizures).